Regulatory Aspects of QUM in India

1. Regulation Including Drug Scheduling (12 Key Schedules)

Schedule C & C1

• Biological and special products (sera, vaccines, hormones, antibiotics for injection).
• Require stringent storage conditions (temperature, light) and special labelling.
• Licensed premises and cold-chain conditions are mandatory.

Schedule D

• Drugs exempt from import restrictions - includes some essential medicines.

Schedule E1

• Poisonous substances (strychnine, arsenic, etc.) that can only be sold with special licence.
• Strict record-keeping of purchase and sale quantities required.

Schedule F, F1, F2, F3

• Standards for biological products and blood products.
• F1: Standards for surgical dressings; F2: Standards for ophthalmic preparations; F3: Standards for IV fluids.

Schedule G

• Drugs that should be taken only under medical supervision.
• Mostly antihistamines and hormonal preparations.
• Label must carry: "Caution: It is dangerous to take this preparation except under medical supervision."
• Can technically be sold without a formal prescription but require pharmacist guidance.

Schedule H (Core Prescription-Only Medicines)

• Lists 536+ drugs (antibiotics, antihypertensives, psychotropics, antiepileptics, antiretrovirals, cytotoxics, etc.).
• Cannot be sold OTC - require a valid prescription from a Registered Medical Practitioner (RMP).
• Label must carry the symbol Rx and the statement: "Schedule H Drug - Warning: To be sold by retail on the prescription of a Registered Medical Practitioner only."
• Prescriptions are valid for a single dispensing event unless "refill" is noted.
• Pharmacist cannot substitute to a different molecule; generic substitution of the same molecule requires prescriber consent.
• No specific register is mandatory for standard Schedule H (unlike H1), but purchase invoices and sale bills must be preserved for 2 years.

Schedule H1 (Enhanced Control Drugs)

• Second-line antibiotics: Cefixime, Ceftriaxone, Levofloxacin, Moxifloxacin, Meropenem, Imipenem, etc.
• Anti-tuberculosis drugs: Rifampicin, Isoniazid, Ethambutol, Pyrazinamide, Pyrazinamide, Capreomycin, Cycloserine.
• Habit-forming / psychotropic: Alprazolam, Diazepam, Zolpidem, Tramadol, Codeine, Buprenorphine, Midazolam.

• Sold only against a valid prescription from an RMP.
• Pharmacist must maintain a separate H1 register recording: patient name, doctor's name and address, drug name, quantity dispensed, date.
• This register must be preserved for 3 years.
• Quantity limits apply for habit-forming drugs.
• Purpose: address antimicrobial resistance (AMR) and curb opioid/benzodiazepine misuse.

Schedule X (Narcotic & Psychotropic Drugs)

• Highest level of control under D&C Rules - drugs of abuse potential (morphine, pethidine, fentanyl, etc.).
• Requires prescription in duplicate from a licensed RMP.
• Pharmacist retains one copy of prescription; records must be kept for 2 years.
• Separately controlled under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985 for broader control.
• Label must carry: "Schedule X Drug."

Schedule J

• Diseases for which no drug or remedy can claim to provide a cure.
• Prevents misleading claims in drug promotion (e.g., cancer, HIV, diabetes being "cured").
• Directly linked to QUM by preventing quackery and false therapeutic claims.

Schedule M

• Good Manufacturing Practices (GMP) for pharmaceutical manufacturers.
• Ensures product quality, safety, and consistency - a foundational requirement for QUM.

Schedule Y

• Requirements and guidelines for import and manufacture of new drugs and conduct of clinical trials.
• Governs pre-clinical and clinical data submission to CDSCO for new drug approval.

How Schedules Are Updated

• The Drugs Technical Advisory Board (DTAB) recommends additions, deletions, or upgrades.
• CDSCO issues gazette notifications to amend schedules.
• Example: The 2013 Amendment introduced Schedule H1; the 2026 notification under Section 26A banned 16 irrational fixed-dose combinations.

2. Regulation of Complementary Medicines

The AYUSH Framework

Key Regulatory Features

• Manufacturing licence issued by State Licensing Authorities (SLA) - not by CDSCO (unlike allopathic drugs).
• Ayurvedic, Siddha, and Unani (ASU) drugs must comply with the Ayurvedic Pharmacopoeia of India (API), Siddha Pharmacopoeia, and Unani Pharmacopoeia respectively.
• Homeopathic drugs are governed by the Homeopathic Pharmacopoeia of India (HPI).
• Schedule E1 controls poisonous plant/animal/mineral ingredients used in ASU formulations.

Challenges in QUM

• Most ASU drugs are sold over the counter freely, even by non-pharmacists - no Rx required.
• No mandatory proof of efficacy equivalent to allopathic clinical trials.
• Heavy metal content (lead, mercury, arsenic in Rasa Shastra formulations) is a safety concern.
• Herb-drug interactions are poorly documented and under-reported.
• Pharmacists in allopathic pharmacies have no legal obligation to counsel on CAM products, though professional guidelines increasingly recommend it.
• The Central Council for Research in Ayurvedic Sciences (CCRAS) and similar bodies conduct post-marketing surveillance, but enforcement is inconsistent.

New Developments

• The Drugs and Cosmetics (Amendment) Rules have introduced Good Agricultural and Collection Practices (GACP) for herbal raw materials.
• The New Drugs and Clinical Trials Rules, 2019 brought the first clinical trial requirements for Ayurvedic "new drugs."
• FSSAI regulates herbal health supplements and nutraceuticals as food products, creating a regulatory overlap.

3. Regulation of OTC Medicines

The Problem: No Formal OTC Category (Historically)

• Drugs with significant side effects (topical steroids, NSAIDs, some antihistamines) were freely dispensed.
• Prescription drugs (Schedule H) were routinely sold without prescriptions in practice.
• No specific labelling, pack size, or consumer information standards existed for de facto OTC products.

Emerging OTC Framework

1. Positive list of OTC drugs - explicit listing rather than passive exclusion from H/X schedules.
2. "Behind the Counter" (BTC) category - drugs not requiring a prescription but sold only under direct pharmacist supervision. This intermediate category (already operational in several European nations) is being piloted through DCC.
3. Rx-to-OTC switch process - a defined regulatory pathway for switching proven-safe prescription drugs to OTC status (no clear process exists yet in India).
4. Mandatory labelling for OTC products: indication, dosage, warnings, contraindications in consumer-friendly language.
5. Pack size limitations for OTC - smaller packs to reduce overdose risk.

Specific Concerns Driving Regulation

• Antibiotic OTC sale: India is one of the largest consumers of antibiotics globally; Schedule H1 antibiotics are still widely sold without prescription, fuelling AMR.
• Topical steroid abuse: The Indian Association of Dermatologists (ITATSA) campaign highlighted widespread OTC misuse of potent topical corticosteroids causing tinea/steroid skin damage.
• Irrational fixed-dose combinations (FDCs): Section 26A of the DCA is periodically invoked to ban irrational FDCs (most recently June 2026, banning 16 FDCs including antibiotic-serratiopeptidase combinations).

4. Professional Responsibility of the Pharmacist

• Pharmacy Act, 1948 - governs registration, education, and practice.
• Pharmacy Practice Regulations, 2015 (Pharmacy Council of India - PCI) - most comprehensive framework for modern pharmacy practice.
• Code of Ethics for Pharmacists (PCI).

Core Professional Duties

1. Dispensing accuracy: Dispense only the drug, dose, strength, and quantity specified on a valid prescription.
2. Prescription verification: Verify authenticity and completeness of prescriptions before dispensing Schedule H/H1/X drugs.
3. No counter-prescribing of prescription drugs: Pharmacists must NOT dispense Rx-only medicines without a valid prescription, except in genuine emergencies (with mandatory follow-up referral).
4. Patient counselling: Provide adequate information on dosage, administration technique, storage, side effects, and drug interactions - especially for Schedule H and H1 drugs.
5. Record keeping: Maintain purchase and sale records; Schedule H1 and X require specific registers preserved for 3 years (H1) and 2 years (X).
6. Refusal of irrational requests: A pharmacist may refuse to dispense if the prescription appears forged, the dose is dangerous, or there is a clear drug interaction risk.

Role in Promoting QUM

• Medication review: Identify and flag potentially inappropriate prescribing (polypharmacy, dose errors, interactions).
• Generic substitution advocacy: Recommend generic alternatives where bioequivalent - promoted under the Jan Aushadhi Scheme (Pradhan Mantri Bhartiya Janaushadhi Pariyojana - PMBJP).
• Pharmacovigilance: Mandatory reporting of Adverse Drug Reactions (ADRs) to the Pharmacovigilance Programme of India (PvPI) coordinated by the Indian Pharmacopoeia Commission (IPC).
• Continuing Pharmacy Education (CPE): PCI regulations require pharmacists to participate in CPE programmes and report compliance to state pharmacy councils.
• Rational drug use promotion: Involvement in Drug and Therapeutics Committees (DTC) in hospitals; updating drug knowledge through continuing education.
• Primary healthcare role: Especially in rural areas where physician access is limited (India's doctor-to-patient ratio ~1:1800), pharmacists are often the first point of care.

Emerging Responsibilities

• BTC medicine supervision: Under the proposed "Behind the Counter" category, pharmacists will formally supervise dispensing without a prescription - this significantly extends legal accountability.
• CAM counselling: While not yet legally mandated, professional guidelines recommend pharmacists integrate awareness of patients' CAM use to prevent herb-drug interactions.
• Digital/e-pharmacy compliance: Emerging regulations on online pharmacies require pharmacist oversight of prescription verification for e-dispensing.

5. Role of Industry in QUM in Medicine Development

Positive Industry Roles

• Industry is expected to follow New Drugs and Clinical Trials (NDCT) Rules, 2019 - requiring robust pre-clinical and Phase I-III clinical evidence before marketing approval.
• Post-marketing surveillance (Phase IV) studies are mandatory for new drugs approved in India for the first 4 years.
• Good Clinical Practice (GCP) guidelines and Schedule Y ensure ethical trial conduct.

• Drug labels and prescribing information (package inserts) must reflect approved indications only.
• Schedule J prevents manufacturers from making curative claims for diseases with no recognised cure.
• CDSCO has mandated standardised package inserts with QR codes (linking to full prescribing information) for improved HCP and patient access to accurate drug information.

• Pharmaceutical companies have a mandatory obligation to:
  • Conduct post-marketing surveillance.
  • Report Serious Adverse Events (SAEs) and unexpected adverse reactions to CDSCO within defined timelines.
  • Maintain pharmacovigilance systems and designated safety officers (under NDCT Rules 2019).
• This data feeds into the PvPI and WHO's global pharmacovigilance database (VigiBase).

• New FDC approvals require demonstration of added therapeutic benefit over individual components.
• DTAB reviews existing FDCs; irrational combinations are banned under Section 26A DCA (e.g., 2016 ban of 344 FDCs; 2026 ban of 16 more irrational combinations).

• Essential Medicines List (National List of Essential Medicines - NLEM): Industry must make NLEM drugs available at price-controlled rates (governed by Drug Price Control Order - DPCO under the Essential Commodities Act).
• Jan Aushadhi Scheme: Government-driven generic medicine access programme; quality-assured generics at reduced cost improve QUM by enabling adherence.

• Drug promotion must comply with the Uniform Code for Pharmaceuticals Marketing Practices (UCPMP), which prohibits:
  • Gifts, cash, or travel benefits to prescribers.
  • Misleading or unsubstantiated promotional claims.
  • Promotion of unapproved indications.
• The UCPMP was voluntary until recent moves to make it mandatory through formal rules.

Industry Threats to QUM (and Regulatory Responses)

Summary Table: Key Schedules and QUM Relevance

Key Regulatory Bodies

• CDSCO (Central Drugs Standard Control Organisation) - apex regulator for allopathic drugs.
• DTAB (Drugs Technical Advisory Board) - technical advisory body for schedule amendments.
• PCI (Pharmacy Council of India) - governs pharmacist education and practice.
• IPC (Indian Pharmacopoeia Commission) - publishes IP standards; runs PvPI.
• Ministry of AYUSH - oversees complementary medicine regulation.
• FSSAI - regulates nutraceuticals/herbal health supplements.
• State Licensing Authorities - grant manufacturing and retail drug licences.

• Drugs and Cosmetics Act, 1940 and Rules, 1945 (Schedules G, H, H1, X, E1, J, M, Y)
• OTC Medicines in India - PMC Review (PMID: 31898596)
• Regulatory, Safety & Economic Aspects of OTC Medicines in India
• Schedule H Compliance Guide 2026
• Pharmacy Practice Regulations, 2015 (PCI)
• New Drugs and Clinical Trials Rules, 2019 (MoHFW)
• GTU Syllabus MCP204T - QUM Regulatory Aspects Unit 4